Effective administration of flavopiridol in advanced-stage chronic lymphocytic leukemia (CLL) is often associated with early biochemical evidence of tumor cell lysis. Previous work using other cell types showed that flavopiridol impacts mitochondria, and in CLL cells flavopiridol down-regulates the mitochondrial protein Mcl-1. We therefore investigated mitochondrial structure and function in flavopiridol-treated CLL patient cells and in the lymphoblastic cell line 697 using concentrations and times at which tumor lysis is observed in treated patients.
INTRODUCTION
Flavopiridol is a semi-synthetic flavone (N-methylpiperidinyl chlorophenyl flavone) that is considered to act broadly as a cyclin-dependent kinase (CDK) inhibitor 1 . However, the in vivo mechanism of action of flavopiridol is not well understood, and may involve actions other than or inclusive of CDK inhibition. Our group recently demonstrated significant clinical efficacy of flavopiridol in patients with refractory chronic lymphocytic leukemia (CLL) using a novel schedule of administration 2 . Approximately 50% of CLL patients who receive flavopiridol using this schedule exhibit biochemical signs of tumor lysis (elevated potassium and phosphate levels, reduced calcium levels) occurring as early as 4.5 hours after treatment initiation. In limited cases with highly elevated peripheral white blood cell counts, this tumor lysis can be severe enough to require dialysis. This observation suggests that flavopiridol, when effectively administered, induces very rapid cell death that is atypical of classical apoptosis. However, more work is needed to understand this process and to better predict which patients may experience severe tumor lysis.
Multiple previous studies in different cell types have incriminated mitochondrial mechanisms in flavopiridol-induced apoptosis, although conditions and timepoints under which this is noted vary widely and are often reported in combination with other agents [3] [4] [5] [6] [7] [8] [9] [10] [11] . Several reports showed that flavopiridol induces mitochondrial membrane disruption and release of cytochrome c in the U937 human monoblastic leukemia cell line and that these effects were potentiated by phorbol myristate acetate (PMA) 4, 9, 10 . This process in U937 cells was noted to be partially caspaseindependent, as a general caspase inhibitor blocked flavopiridol-induced loss of mitochondrial membrane potential (ΔΨ m ) but not cytochrome c release. Using human glioma cell lines, Alonso et al. also reported that flavopiridol induces caspase-independent cell death, and although cytochrome c release was not observed in these cells, apoptosis inducing factor (AIF) was cell lines, inhibition of caspases blocked apoptosis but not early loss of ΔΨ m 11 . Thus, although there is substantial evidence for the involvement of mitochondria in flavopiridol-induced cytotoxicity, the mechanism is still unclear and differs by cell type.
Several groups have demonstrated that the anti-apoptotic protein Mcl-1 is rapidly downregulated following flavopiridol treatment at both the mRNA and protein levels [14] [15] [16] . Mcl-1 contributes significantly to mitochondrial membrane stability, both through sequestering proapoptotic factors such as Bax 17 and through inhibition of mitochondrial calcium signaling 18 .
Mitochondria play a major role in calcium homeostasis through the rapid uptake of calcium released from intracellular stores such as the endoplasmic reticulum (ER) 19 . Increased calcium uptake via the calcium uniporter favors the opening of the PTP, resulting in movement of ions and solutes along their respective electrochemical gradients and expansion of the mitochondrial matrix space, culminating in disruption of the outer mitochondrial membrane and the liberation of pro-apoptotic factors from the intramembranous space 19, 20 . This sequence of events is referred to as the mitochondrial permeability transition (MPT). Thus, the indirect inhibition of intracellular calcium flux by Mcl-1 provides an additional explanation of its anti-apoptotic effect.
Down-regulation of Mcl-1 is known to potentiate the effects of anticancer agents in several tumor types, and is sufficient to cause apoptosis in leukemic cell lines and CLL patient cells 21 .
Because of these factors, we sought to determine if the ability of flavopiridol to induce rapid cell death in CLL patient cells involves mitochondria and to understand the cellular events surrounding this effect. Determining the mechanism of mitochondrial perturbation will be essential to understanding flavopiridol's activity in CLL and may help to predict which patients are at increased risk for acute tumor lysis syndrome with treatment. 
MATERIALS AND METHODS

CLL
Apoptosis and Mitochondrial Membrane Depolarization Studies: Apoptosis and cytotoxicity
were assessed using annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI) (BD Biosciences, San Diego, CA) and an EPICS-XL flow cytometer (Beckman Coulter, Fullerton, CA). Mitochondrial membrane potential changes were assessed using the voltagesensitive lipophilic cationic dye 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolyl carbocyanine iodide (JC-1) (Molecular Probes, Eugene, OR) as described 21 . In these analyses, a gate was drawn around the population with aggregated JC-1 (intact mitochondria) in untreated cells. Using this gate, the percent cells with intact mitochondria in treated samples was then calculated relative to the untreated sample, set at 100%. Statistical Methods: All experiments were analyzed using the raw data in random effects models to allow for correlations among measures from the same patient or cell line. If a particular group in an experiment was used in multiple comparisons, p-values were adjusted by Holm's method.
Protein Fractionation and
All tests were two-sided and the significance level set at α=0.05.
RESULTS
Flow cytometric analysis of flavopiridol-treated CLL cells:
Because of the early and sometimes dramatic evidence of tumor cell death in CLL patients treated with flavopiridol, we conducted in vitro kinetic studies to determine the time course of flavopiridol activity on CLL cells using media containing human serum and a flavopiridol concentration similar to what is achieved in treated patients 2 . We observed a gradual but significant loss in ΔΨ m by 6 h as evidenced by disaggregation of JC-1 (figure 1a). This effect was concurrent with increased annexin binding indicative of early stages of apoptosis, although no increase in PI uptake was noticed during this period. We also studied drug washout after 4 h, measuring effects on viability and mitochondrial depolarization at 6 h. There was no difference between the continuous exposure for 6 h vs.
washout, likely due to rapid uptake and/or short in vitro half-life of flavopiridol (data not shown). To better understand the situation in CLL patients treated with flavopiridol, we then incubated whole blood from patients with or without 3.0 μM flavopiridol for up to 6 h. CD19-positive cells were then quickly isolated and analyzed as above (figure 1b). In these experiments mitochondrial depolarization occurred by 6 h as in isolated cells, but to a lesser extent.
Furthermore, mitochondrial depolarization was consistently observed prior to increases in annexin binding. 38 In two separate experiments, we did not observe translocation of the cytosolic protein Bax into the mitochondrial fraction of CLL patient cells, as reported previously using epithelial and fibroblast cell lines 39 . Also, we noted only minor increases in cytochrome c in cytoplasm following flavopiridol treatment (figure 5b), without a significant decrease in the mitochondria fraction (not shown).
Investigation of apoptosis pathways activated by flavopiridol:
For When CLL cells incubated with flavopiridol for 6 h were treated with CCCP, oxygen consumption was preserved as evidenced by a significant increase in OCR, indicating that flavopiridol does not permanently disrupt the mitochondrial electron transport mechanism.
Flavopiridol induces early morphological changes in CLL patient cells: Transmission Electron
Microscopy (TEM) is a powerful technique to document subcellular structural changes that may be the result of processes such as apoptosis or autophagy. To determine whether changes in specific organelles could be associated with flavopiridol, we collected images of CLL cells treated with flavopiridol for 6 h. Cells were treated in whole blood to minimize effects on mitochondria due to extraneous or unknown factors in standard culture conditions, then quickly isolated and fixed before being processed for microscopy. The TEM images reveal multiple changes in flavopiridol-treated cells ( figure 7) . While some cells in the flavopiridol-treated samples showed nuclei similar to the untreated control, others exhibited a lobed or segmented appearance typical of apoptotic nuclei. Also visible in some but not all cells was substantial swelling of mitochondria and loss of cristae definition, although in other cells mitochondria appeared ultrastructurally similar to the control. We additionally observed an increased frequency of mitochondria surrounded by double membrane structures, which is consistent with the lysosomal clearance of mitochondria (autophagy) 40 . It is important to note that although these differences in mitochondrial structure were increased in flavopiridol-treated samples, they were variable among cells within the sample. This may be simply due to variations in the rate of apoptosis among the population of treated cells, although mitochondria are also known to be heterogeneous within cells in both morphology and function 41 . Evidence of mitochondrial swelling and loss of cristae definition were also noted in untreated specimens, albeit at a lower frequency, suggesting that apoptosis was underway in these samples as well. Also detectable in some flavopiridol-treated cases was "cristae remodeling", as described by Kroemer et al. 36 This appears under TEM as electron dense regions within otherwise intact mitochondria (data not shown). This reorganization of cristae is thought to promote mobilization of proteins such as cytochrome c in the mitochondrial intramembrane space. Permeabilization of the mitochondrial membrane may then be the final event that would allow the release of these proteins into cytoplasm 36, 42 . is not rescued by either a pan-caspase inhibitor or specific inhibitors of caspase-8 and caspase-9, this process is either caspase-independent or lies upstream of caspase activation. Furthermore, Puppo et al. 43 showed that treatment of human neuroblastoma cells with flavopiridol causes an early activation of caspase-3 prior to the extensive cell death, similar to what we reported previously in CLL patient cells 44 . However, in this report, caspase-8 and caspase-9 were not activated, suggesting that in flavopiridol-mediated cytotoxicity caspase-3 may be acting upstream of these activator caspases. While we have not addressed this directly, our data do not support a role for calpains in flavopiridol-mediated mitochondrial membrane depolarization, although calpains may be involved in cell death subsequent to flavopiridol treatment 45, 46 . We were unable to prevent flavopiridol-induced loss of mitochondrial membrane potential using the caspase inhibitor Z-VAD-fmk, which also inhibits calpains by preventing caspase-mediated activation 47, 48 . Additionally, Kitada et al. 14 variability is unknown, it may in part explain the different flavopiridol sensitivity seen between samples. Although we were able to determine that the calcium source was intracellular using EGTA, further attempts to precisely identify this source were unsuccessful. In our experiments both thapsigargin and BAPTA-AM, which alter intracellular calcium levels via different mechanisms, potently induced early mitochondrial depolarization. This depolarization was followed by substantial apoptosis as measured by annexin binding. As intracellular calcium is known to affect a large array of factors including mitochondrial stability and cell survival 50 have not yet examined the relationship between pre-treatment expression levels of Bcl-2 family members and the response of CLL patients to flavopiridol treatment. However, in contrast to our in vitro findings, Pepper et al 29 noted that changes in Bcl-2:Bax expression ratios, which influence the sensitivity of the PTP to opening, were not associated with CLL cell sensitivity to flavopiridol in vitro. Rather than protecting against the PTP, it is interesting to speculate that overexpression of Bcl-2 compensates for Mcl-1 suppression, thereby normalizing mitochondrial calcium homeostasis 54 .
DISCUSSION
The interrelations between calcium flux, ΔΨ m and OCR are varied and complex. Billard et al. 55 showed that in CLL cells, inducible nitric oxide synthase is constitutively expressed and can be inhibited with 3-9 h flavopiridol treatment. As nitric oxide is a potent regulator of mitochondrial induced by chlorambucil which is typically associated with mitochondrial shrinkage 57 , the mitochondria of flavopiridol-treated CLL cells tended to be swollen with signs of autolysis, similar to that recently shown by Sun et al. 58 Furthermore, we observe increased prevalence of mitochondrial clusters surrounded by double membranes consistent with an autophagic phenotype. In this regard, recent studies indicate that collapse of ΔΨ m triggers activation of intrinsic mitochondrial calcium-independent lipase (iPLA 2 ), which promotes self degradation (autolysis) 59 and influences cytochrome c release 60 . Autolysis ultimately leads to mitochondrial clearance by lysosomes (autophagy), and when many mitochondria are involved, this process may trigger apoptotic cell death 61 . As noted in many of our experiments, at this early timepoint (6 h), annexin binding was minimal and PI uptake is the same as untreated controls. This
indicates that flavopiridol has a negligible effect on plasma membrane integrity at this early In conclusion, our data indicate that mitochondrial deenergization triggered by Bcl-2 sensitive and Bcl-X L appear to suppress these mitochondrial events, apparently by maintaining calcium homeostasis and mitochondrial respiration through PTP-independent mechanisms. Additional studies will be needed to establish how flavopiridol causes the inhibition of mitochondrial respiration in CLL cells and to better define the role of Bcl-2 family proteins in this process.
Finally, the ex vivo techniques for assessing sensitivity of CLL cells to flavopiridol described here may prove useful for identifying patients who will have a response to flavopiridol, as well as those who are at increased risk of acute tumor lysis syndrome. 
